Biosimilar monoclonal antibodies: Preclinical and clinical development aspects

Clinical and Experimental Rheumatology

Volumn 34, Issue 4, 2016, Pages 698-705

  Gonçalves, João ^a   Araújo, Filipe ^b,c   Cutolo, Maurizio ^d   Fonseca, João Eurico ^c  

^a RESEARCH INSTITUTE FOR MEDICINES IMED ULISBOA   (Portugal)

^b Hospital Ortopédico de Sant Ana   (Portugal)

^c UNIVERSITY OF LISBON   (Portugal)

^d UNIVERSITY OF GENOA   (Italy)

Author keywords

Ankylosing spondylitis; Anti rheumatic agents; Biosimilar pharmaceuticals; CT P13; Inflammatory bowel disease; Rheumatoid arthritis; Therapeutic equivalence

Indexed keywords

ADALIMUMAB; BIOSIMILAR AGENT; DRUG ANTIBODY; FC RECEPTOR; INFLIXIMAB; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; RITUXIMAB; TUMOR NECROSIS FACTOR; ANTIINFLAMMATORY AGENT; ANTIRHEUMATIC AGENT; GASTROINTESTINAL AGENT; GENERIC DRUG;

ANKYLOSING SPONDYLITIS; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; AREA UNDER THE CURVE; BIOEQUIVALENCE; DRUG APPROVAL; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG IMPURITY; DRUG MANUFACTURE; DRUG QUALITY; DRUG SAFETY; HUMAN; IMMUNOGENICITY; INFLAMMATORY BOWEL DISEASE; NONHUMAN; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; PURE RED CELL ANEMIA; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; STUDY DESIGN; ANIMAL; CLINICAL TRIAL (TOPIC); IMMUNOLOGY; INFLAMMATORY BOWEL DISEASES; PATENT; PATIENT SAFETY; PRECLINICAL STUDY; PROCEDURES; QUALITY CONTROL; RHEUMATIC DISEASES; RISK ASSESSMENT; STANDARDS; THERAPEUTIC EQUIVALENCE; TREATMENT OUTCOME;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; BIOSIMILAR PHARMACEUTICALS; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; DRUG EVALUATION, PRECLINICAL; DRUGS, GENERIC; GASTROINTESTINAL AGENTS; HUMANS; INFLAMMATORY BOWEL DISEASES; PATENTS AS TOPIC; PATIENT SAFETY; QUALITY CONTROL; RHEUMATIC DISEASES; RISK ASSESSMENT; THERAPEUTIC EQUIVALENCY; TREATMENT OUTCOME;

EID: 84984813317     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. US FOOD AND DRUG ADMINISTRATION: Biosimilars. Available at: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/How-DrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/(Accessed 3 January 2016).
2. EUROPEAN MEDICINES AGENCY: Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003920.pdf (Accessed 23 May 2013).
3. WEISE M, BIELSKY MC, de SMET K et al.: Biosimilars-why terminology matters. Nat Biotechnol 2011; 29: 690-3.
4. EUROPEAN MEDICINES AGENCY: Guideline on similar biological medicinal products containting biotechnology-derived proteins as active substance: quality issues. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003953.pdf (Accessed 23 May 2013).
5. EUROPEAN MEDICINES AGENCY: Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003947.pdf (Accessed 23 May 2013).
6. US FOOD AND DRUG ADMINISTRATION: Scientific considerations in demonstrating biosimilarity to a reference product. Guidance for Industry. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf (Accessed 5 September 2015).
7. LEE JF, LITTEN JB, GRAMPP G: Comparability and biosimilarity: considerations for the healthcare provider. Curr Med Res Opin 2012; 28: 1053-8.
8. MELLSTEDT H: Anti-neoplastic biosimilars-the same rules as for cytotoxic generics cannot be applied. Ann Onc 2013; 24 (Suppl. 5): v23-8.
9. EUROPEAN MEDICINES AGENCY: Guideline on similar biological medicinal products containing monoclonal antibodies-non-clinical and clinical issues. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500128686.pdf (Accessed 23 May 2013).
10. SCHIESTL M, LI J, ABAS A et al.: The role of the quality assessment in the determination of overall biosimilarity: a simulated case study exercise. Biologicals 2014; 42: 128-32.
11. ZALAI D, DIETZSCH C, HERWIG C: Riskbased process development of biosimilars as part of the Quality by Design Paradigm. PDA J Pharm Sci Technol 2013; 67: 569-80.
12. MARTIN-MOE S, LIM FJ, WONG RL, SREEDHARA A, SUNDARAM J, SANE SU: A new roadmap for biopharmaceutical drug product development: integrating development, validation, and quality by design. J Pharm Sci 2011; 100: 3031-43.
13. COOK J, CRUAñES MT, GUPTA M, RILEY S, CRISON J: Quality-by-design: are we there yet? AAPS Pharm Sci Tech 2014; 15: 140-8.
14. EUROPEAN MEDICINES AGENCY: European assessment reports for authorised medicinal products for human use. Available at: http://www.ema.europa.eu/ema/index.jsp?curl_pages/medicines/landing/epar_search.jsp&murl_menus/medicines/medicines.jsp&mid_WC0b01ac058001d125 (Accessed 1 October 2014)
15. McKEAGE K: A Review of CT-P13: An infliximab biosimilar. BioDrugs 2014; 28: 313-21.
16. McCAMISH M, WOOLLETT G: The continuum of comparability extends to biosimilarity: how much is enough and what clinical data are necessary? Clin Pharmacol Ther 2013; 93: 315-7.
17. WEISE M, KURKI P, WOLFF-HOLZ E, BIELSKY MC, SCHNEIDER CK: Biosimilars: the science of extrapolation. Blood 2014; 124: 3191-6.
18. SCHNEIDER CK: Biosimilars in rheumatology: the wind of change. Ann Rheum Dis 2013; 72: 315-8.
19. ICH HARMONIZED TRIPARTITE GUIDELINE: Comparability of biotechnological/biological products subject to changes in their manufacturing process. Available at http://www.ich.org/products/guidelines.html (Accessed 1 October 2014).
20. WOJCIECHOWSKI PW, SMIT HI, MYERS MM et al.: Making changes to a biopharmaceutical manufacturing process during development and commercial manufacturing: The REMICADE® Story. In ABHINAV A. SHUKLA, MARK R. ETZEL, SHISHIR GADAM, (Eds): In Process Scale Bioseparations for the Pharmaceutical Industry. CRC Press 2006: 507-22.
21. SCHIESTL M, STANGLER T, TORELLA C, CEPELJNIK T, TOLL H, GRAU R: Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol 2011; 29: 310-2.
22. AAPRO M, CORNES P: Biosimilars in oncology: emerging and future benefits. Eur J Oncol Pharm 2012; 6: 27-9.
23. HöER ADM, C, HäUSSLER B, HAUSTEIN R: Saving money in the European healthcare systems with biosimilars. Generics and Biosimilars Initiative Journal (GaBI Journal) 2012; 1: 120-6.
24. AAPRO M, CORNES P, SUN D, ABRAHAM I: Comparative cost efficiency across the European G5 countries of originators and a biosimilar erythropoiesis-stimulating agent to manage chemotherapy-induced anemia in patients with cancer. Ther Adv Med Oncol 2012; 4: 95-105.
25. VERPOORT K, MOHLER TM: A non-interventional study of biosimilar granulocyte colonystimulating factor as prophylaxis for chemotherapy-induced neutropenia in a community oncology centre. Ther Adv Med Oncol 2012; 4: 289-93.
26. ARAúJO F, CORDEIRO I, TEIXEIRA F, GONçALVES J, FONSECA JE: Pharmacology of biosimilar candidate drugs in Rheumatology: a literature review. Acta Reumatol Port 2014; 39: 19-26.
27. WEISE M, BIELSKY MC, de SMET K et al. Biosimilars: what clinicians should know. Blood 2012; 120: 5111-7.
28. BRINKS V, HAWE A, BASMELEH AH et al.: Quality of original and biosimilar epoetin products. Pharm Res 2011; 28: 386-93.
29. PRADITPORNSILPA K, TIRANATHANAGUL K, KUPATAWINTU P et al.: Biosimilar recombinant human erythropoietin induces the production of neutralizing antibodies. Kidney Int 2011; 80: 88-92.
30. US FOOD AND DRUG ADMINISTRATION: Quality Considerations in Demonstrating Biosimilarity to a Reference Protein Product. Available at: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm291134.pdf (Accessed 5 September 2015).
31. US FOOD AND DRUG ADMINISTRATION: Biosimilars: Additional Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009. Available at: http://www.fda.gov/downloads/Drugs/./Guidances/UCM273001.pdf (Accessed 5 September 2015).
32. EUROPEAN MEDICINES AGENCY: Guideline on the Investigation of Bioequivalence. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500070039.pdf (Accessed 23 May 2013).
33. PM, ZOU L, SADHU C, SHEN WD, NOCK S: Comparative immunogenicity assessment: a critical consideration for biosimilar development. Bioanalysis 2015; 7: 373-81.
34. EUROPEAN MEDICINES AGENCY: Guideline on immunogenicity assessment of monoclonal antibodies intended for in vivo clinical use. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500128688.pdf (Accessed 13 March 2016).
35. McCAMISH M, WOOLLETT G: The continuum of comparability extends to biosimilarity: how much is enough and what clinical data are necessary? Clin Pharmacol Ther 2013; 93: 315-7.
36. EUROPEAN MEDICINES AGENCY: Assessment report-Inflectra. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002778/WC500151490.pdf (Accessed 1 October 2014).
37. WAETZIG GH, ROSENSTIEL P, NIKOLAUS S, SEEGERT D, SCHREIBER S: Differential p38 mitogen-activated protein kinase target phosphorylation in responders and nonresponders to infliximab. Gastroenterology 2003; 125: 633-4.
38. MITOMA H, HORIUCHI T, TSUKAMOTO H et al.: Mechanisms for cytotoxic effects of antitumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab. Arthritis Rheum 2008; 58: 1248-57.
39. MOROI R, ENDO K, KINOUCHI Y et al.: FCGR3A-158 polymorphism influences the biological response to infliximab in Crohn's disease through affecting the ADCC activity. Immunogenetics 2013; 65: 265-71.
40. SOON KWAN JUNG, KYOUNG HOON LEE, JAE WON JEON et al.: Physicochemical characterization of Remsima®. mAbs 2014; 6: 1163-77.
41. ARAúJO F, GONçALVES J, FONSECA JE: Biosimilar DMARDs: What does the future hold? Drugs 2016 Mar 3 [Epub ahead of print].
42. BEN-HORIN S, YAVZORI M, BENHAR I et al.: Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima. Gut 2015 Apr 20 [Epub ahead of print].
43. PARK SH, KIM YH, LEE JU et al.: Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea. Expert Rev Gastroenterol Hepatol 2015; (S1): 35-44.
44. JUNG Y S, PARK D I, KIM Y H et al.: Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: a retrospective multicenter study. J Gastroenterol Hepatol 2015 May 14 [Epub ahead of print].
45. KANG YS, MOON HH, LEE SE, LIM YJ, KANG HW: Clinical experience of the use of CTP13, a biosimilar to infliximab in patients with inflammatory bowel disease: a case series. Dig Dis Sci 2015; 60: 951-6.
46. GECSE K, FARKAS K, LOVASZ B et al.: Biosimilar infliximab in inflammatory bowel diseases: first interim results from a prospective nationwide observational cohort. J Crohns Colitis 2015; 9(S1): S234-5; P314.
47. MOLNAR T, FARKAS K, RUTKA M et al.: Efficacy of the new infliximab biomarker CTP13 induction therapy on mucosal healing in ulcerative colitis patients. J Crohns Colitis 2015; 9(S1): S382; P603.
48. JAHNSEN J, DETLIE TE, VATN S, RICANEK P: Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study. Expert Rev Gastroenterol Hepatol 2015; 9(S1): 45-52.
49. JARZEBICKA D, PLOCEK A, SIECZKOWSKA J et al.: First observations of the use of biosimilar infliximab for treatment of ulcerative colitis in paediatric population. J Crohns Colitis 2015; 9(S1): S307-8; P456.
50. SIECZKOWSKA J, BANASZKIEWICZ A, PLOCEK A et al.: Assessment of safety and efficacy of biosimilar infliximab in children with Crohn disease: a preliminary report. J Crohns Colitis 2015; 9(S1): S295; P430.
51. JARZEBICKA D, BANASZKIEWICZ A, PLOCEK A et al.: Preliminary assessment of efficacy and safety of switching between originator and biosimilar infliximab in paediatric Crohn disease patients. J Crohns Colitis 2015; 9(S1): S224-5; P295
52. MURPHY C, SUGRUE K, MOHAMED G et al.: Biosimilar but not the same. J Crohns Colitis 2015; 9(S1): S331-2; P505.
53. REINISCH W, LOUIS E, DANESE S: The scientific and regulatory rationale for indication extrapolation: a case study based on the infliximab biosimilar CT-P13. Expert Rev Gastroenterol Hepatol 2015; 9(S1): 17-26.
54. BUI LA, TAYLOR C: Developing Clinical Trials for Biosimilars. Semin Oncol 2014; 41: S15-S25.
55. BECK A, REICHERT JM: Approval of the first biosimilar antibodies in Europe: a major landmark for the biopharmaceutical industry. mAbs 2013; 5: 621-3.
56. SKINGLE D: Biosimilars: what do patients need to consider? RMD Open 2015; 1: e000141.
57. ISAACS JD, CUTOLO M, KEYSTONE EC, PARK W, BRAUN J: Biosimilars in immune-mediated inflammatory diseases: initial lessons from the first approved biosimilar anti-tumour necrosis factor monoclonal antibody. J Intern Med 2016; 279: 41-59.